TWM
RXRX icon

Tradition Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Tradition Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.53K Buy
+500
New +$1.93K ﹤0.01% 526

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tradition Wealth Management's RXRX Position: Q1 2026 in Review

Tradition Wealth Management increased its Recursion Pharmaceuticals (RXRX) stake by 2% in Q1 2026, buying an estimated $5.12K and bringing the position to 67,738 shares worth $208K. The position accounts for 0.01% of the portfolio, ranked #470.

Tradition Wealth Management first reported a position in RXRX in Q3 2023 and has held it in 5 quarters since. The position peaked at $272K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Tradition Wealth Management held 67,738 shares of Recursion Pharmaceuticals worth $208K as of Q1 2026.
  • Tradition Wealth Management bought 1,325 Recursion Pharmaceuticals shares in Q1 2026, an estimated $5.12K.
  • Recursion Pharmaceuticals made up 0.01% of Tradition Wealth Management's portfolio in Q1 2026, its #470 holding.
  • Tradition Wealth Management first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 5 quarters since.
  • Tradition Wealth Management's Recursion Pharmaceuticals position peaked at $272K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Tradition Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.